【etrnya】評論
Raltegravir (RAL, Isentress, formerly MK-0518) is an antiretroviral drug produced by Merck & Co., used to treat HIVinfection.[1] It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval
【陳育惠】評論
(A)saquinavir(B)raltegravir ----- Integrase inhibitor 整合酶抑制劑(C)lopinavir(D)darunavir